The abstract is read at the publisher; the summary is JClub's.
An early-stage synthetic immunological niche (IN) gene signature in non-obese diabetic (NOD) mice stratifies progressors from non-progressors by 6 weeks and is conserved in human T1D tissues.
- Why it matters: Type 1 Diabetes (T1D) onset and immunotherapy responses vary, implying stage-specific immune dysregulation that has not been clearly defined.
- What they did: Subcutaneous microporous polycaprolactone scaffolds were used for multimodal IN profiling with longitudinal transcriptomics in NOD mice, and the resulting gene signature was tested in human spleen and pancreatic lymph node versus peripheral blood.
- The result: IN profiling linked macrophage-associated TNFα pathway enrichment in pancreas of NOD progressors and validated it in human T1D islets, while IN-derived genesets produced a response score that prospectively separated anti-TNFα-sensitive from resistant mice.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.